Tibolone osteoporosis

However, as others have pointed out, the long-term safety and efficacy of tibolone on major health outcomes in younger postmenopausal women are unknown [84. In older, mostly white, women with osteoporosis, tibolone 1.25 mg/day for 3 years seemed in earlier studies to have a beneficial effect on the breast... 

Hormone replacement therapy (HRT), including tibolone, is not recommended for postmenopausal women over the age of 50 years unless other treatments for osteoporosis are contraindicated or not tolerated (MHRA, 2005). 

Tibolone (Livial) is widely used in treatment of vasomotor symptoms and prevention of osteoporosis. The parent compound itself is devoid of activity, but it is metabolized in a tissue-selective manner to three metabolites that have predominantly estrogenic, progestogenic, and androgenic activities. The drug appears to increase bone mineral density and decrease vasomotor symptoms without stimulating the endometrium, but its effects on fractures, breast cancer, and long-term outcomes remain to be established. 

---